First Product Launch


January 2015 – Marking one of the chief milestones of the Company since inception, Sienna is delighted to announce its agreement with the leading US uropathology lab, Bostwick Laboratories® who will offer the world-first stain for the detection of telomerase.

Bostwick Laboratories will now use Sienna reagent Anti-hTERT antibody SCD-A7™, a monoclonal antibody against telomerase, as part of their new CytologyPro XT™ test. Results to date show their new test may have the potential to assist with challenging calls in standard cytology related to low-grade disease and atypia.  

Sienna’s CEO Dr.Hegarty added, “For Sienna shareholders, this agreement is exciting as it represents the first stream of product revenues for the company. This is only the first of several potential applications of SCD-A7™ and our team is working hard to expand our geographic presence, including in Australia and other regions, as well as developing the platform for additional applications.”

First product registration with FDA and company revenues begin


No Very

Captcha Image

Sign up for updates